Peroral amphotericin B polymer nanoparticles lead to comparable or superior In Vivo antifungal activity to that of intravenous Ambisome® or Fungizone™

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Italia, Jagdishbhai L ^a   Sharp, Andrew ^b   Carter, Katharine C ^a   Warn, Peter ^b   Kumar, M N V Ravi ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DIMETHYL SULFOXIDE; NANOPARTICLE; POLYGLACTIN; POSACONAZOLE; ACETONE; ANTIFUNGAL AGENT; POLYMER; SOLVENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SYNTHESIS; IN VIVO STUDY; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; MOLECULAR SIZE; MOUSE; NANOENCAPSULATION; NONHUMAN; PROCESS OPTIMIZATION; SINGLE DRUG DOSE; ANIMAL; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

MURINAE;

ACETONE; ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DIMETHYL SULFOXIDE; INJECTIONS, INTRAVENOUS; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MICE; NANOPARTICLES; POLYMERS; RATS, SPRAGUE-DAWLEY; SOLVENTS;

EID: 80053613500     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025744     Document Type: Article

References (25)

1. Erjavec Z, Kluin-Nelemans H, Verweij PE, (2009) Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin Microbiol Infect 15: 625-633.
2. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, et al. (2009) Epidemiology and outcome of invasive fungal infection in adulthematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 48: 265-273.
3. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, et al. (2010) Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 50: 338-344.
4. Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, et al. (2010) Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 61: 259-265.
5. Dagenais TR, Keller NP, (2009) Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis. Clin Microbiol Rev 22: 447-465.
6. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA, (2007) Invasive aspergillosis following hematopoietic cell transplantation:outcomes and prognostic factors associated with mortality. Clin Infect Dis 44: 531-540.
7. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, et al. (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10: 184-194.
8. Singh UK, Prasad R, Jaiswal BP, Singh PK, Thakur CP, (2010) Amphotericin B Therapy in Children with Visceral Leishmaniasis: Daily vs. Alternate Day, a Randomized Trial. J Trop Pediatr 56: 321-324.
9. Egger SS, Meier S, Leu C, Christen S, Gratwohl A, et al. (2009) Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant 45: 1197-1203.
10. Denning DW, (1996) Therapeutic outcome of invasive aspergillosis. Clin Infect Dis 23: 608-615.
11. Annaloro C, Olivares C, Usardi P, Onida F, Della Volpe A, et al. (2009) Retrospective evaluation of amphotericin B deoxycholate toxicity in a single centre series of haematopoietic stem cell transplantation recipients. J AntimicrobChemother 63: 625-626.
12. Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL, (2003) Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 254: 73-75.
13. Delmas G, Park S, Chen ZW, Tan F, Kashiwazaki R, et al. (2002) Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother 46: 2704-2707.
14. Wasan EK, Bartlett K, Gershkovich P, Sivak O, Banno B, Wong Z, et al. (2009) Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm 372: 76-84.
15. Italia JL, Yahya MM, Singh D, Kumar MNVR, (2009) Biodegradable nanoparticles improve oral bioavailability of Amphotericin B and shows reduced nephrotoxicity against intravenous Fungizone®. Pharm Res 26: 1324-1331.
16. Murakamia H, Kobayashi M, Takeuchi H, Kawashima Y, (2000) Further application of a modified spontaneous emulsification solvent diffusion method to various types of PLGA and PLA polymers for preparation of nanoparticles. Powder Tech 107: 137-143.
17. Peltonen L, Koistinen P, Karjalainen M, Häkkinen A, Hirvonen J, (2002) The effect of cosolvents on the formulation of nanoparticles from low molecular-weight poly(l)lactide. AAPS Pharm Sci Tech 3: 52-58.
18. Xiong JY, Liu XY, Chen SB, Chung TC, (2005) Preferential solvation stabilization for hydrophobic polymeric nanoparticle fabrication. J Phys Chem B 109: 13877-13882.
19. Galindo-Rodriguez S, Allémann E, Fessi H, Doelker E, (2004) Physicochemical parameters associated with nanoparticles formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res 21: 1428-1439.
20. Risovic V, Rosland M, Sivak O, Wasan KM, Bartlett K, (2007) Assessing the antifungal activity of a new oral lipid-based amphotericin B formulation following administration to rats infected with Aspergillus fumigatus. Drug Dev Ind Pharm 33: 703-707.
21. Allémann E, Leroux J, Gurny R, (1998) Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev 34: 171-189.
22. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, et al. (2005) Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res 23: 184-195.
23. Bhardwaj V, Hariharan S, Bala I, Lamprecht A, Kumar N, et al. (2005) Pharmaceutical aspects of polymeric nanoparticles for oral delivery. J Biomed Nanotech 1: 235-258.
24. Sheppard DC, Graybill JR, Najvar LK, Chiang LY, Doedt T, et al. (2006) Standardization of an experimental murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 50: 3501-3503.
25. Warn PA, Sharp A, Morrissey G, Denning DW, (2010) Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and-resistant strains of Aspergillus fumigatus. Int J Antimicrob Agents 35: 146-151.